NAICS 325413: In
This U.S. industry comprises establishments primarily engaged in manufacturing in-vitro (i.e., not taken internally) diagnostic substances, such as chemical, biological, or radioactive substances. The substances are used for diagnostic tests that are performed in test tubes, petri dishes, machines, and other diagnostic test-type devices.

ExioML sector: Chemicals nec
Region: US | Year: 2022
Sector value added: 183879.917188 M EUR | Employment: 2033.54236812 thousand persons
Sector GHG emissions: 125728834468.0 kg CO2 eq | Energy carrier net total: 3186425.50957 TJ | Carbon intensity: 0.6837551179635024

Company: Aspira Womens Health Inc
Aspira Women's Health Inc. operates as a biotech company. The Company focuses on discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. Aspira Women's Health offers portfolio of blood tests to aid in the detection of ovarian cancer in women.